PURPOSE: To identify the role of epithelial cellular adhesion molecule (EpCAM) in gastric cancer growth and explore the potential value of EpCAM monoclonal antibody as new therapeutic strategy for gastric cancer. METHODS: The expression of EpCAM was determined by immunohistochemistry staining in gastric cancer tissues, RT-PCR and Western blot in cell lines. EpCAM expression in cell lines was downregulated by small interfering RNA. Then the effects of EpCAM on gastric cancer cell growth in vivo and in vitro were determined by MTT, FCM analysis, clone formation assay and tumor formation assay. Additionally, western blot was used to detect the effect of EpCAM on cell cycle-relevant factor cyclin D1. RESULTS: EpCAM was found to be overexpressed in gastric cancer tissues and cell lines. Downregulation of EpCAM resulted in a decrease of cell proliferation and cell cycle arrest in AGS and SGC7901 cells, which had high endogenous EpCAM expression. EpCAM downregulation also suppressed tumor formation in nude mice. Moreover, EpCAM repression in gastric cancer cells could downregulate cyclin D1. CONCLUSIONS: EpCAM was a potential oncogene and contributed to the growth of gastric cancer. Our data first provided compelling evidence of potential value of EpCAM in the therapy of gastric cancer in clinic.
PURPOSE: To identify the role of epithelial cellular adhesion molecule (EpCAM) in gastric cancer growth and explore the potential value of EpCAM monoclonal antibody as new therapeutic strategy for gastric cancer. METHODS: The expression of EpCAM was determined by immunohistochemistry staining in gastric cancer tissues, RT-PCR and Western blot in cell lines. EpCAM expression in cell lines was downregulated by small interfering RNA. Then the effects of EpCAM on gastric cancer cell growth in vivo and in vitro were determined by MTT, FCM analysis, clone formation assay and tumor formation assay. Additionally, western blot was used to detect the effect of EpCAM on cell cycle-relevant factor cyclin D1. RESULTS:EpCAM was found to be overexpressed in gastric cancer tissues and cell lines. Downregulation of EpCAM resulted in a decrease of cell proliferation and cell cycle arrest in AGS and SGC7901 cells, which had high endogenous EpCAM expression. EpCAM downregulation also suppressed tumor formation in nude mice. Moreover, EpCAM repression in gastric cancer cells could downregulate cyclin D1. CONCLUSIONS:EpCAM was a potential oncogene and contributed to the growth of gastric cancer. Our data first provided compelling evidence of potential value of EpCAM in the therapy of gastric cancer in clinic.
Authors: Daniele Generali; Alfredo Berruti; Maria P Brizzi; Leticia Campo; Simone Bonardi; Simon Wigfield; Alessandra Bersiga; Giovanni Allevi; Manuela Milani; Sergio Aguggini; Valeria Gandolfi; Luigi Dogliotti; Alberto Bottini; Adrian L Harris; Stephen B Fox Journal: Clin Cancer Res Date: 2006-08-01 Impact factor: 12.531
Authors: Gilbert Spizzo; Peter Obrist; Christian Ensinger; Igor Theurl; Martina Dünser; Angela Ramoni; Eberhard Gunsilius; Günther Eibl; Gregor Mikuz; Günther Gastl Journal: Int J Cancer Date: 2002-04-20 Impact factor: 7.396
Authors: David B Seligson; Allan J Pantuck; Xueli Liu; Yunda Huang; Steven Horvath; Matthew H T Bui; Ken-ryu Han; Adrian J L Correa; Mervi Eeva; Sheila Tze; Arie S Belldegrun; Robert A Figlin Journal: Clin Cancer Res Date: 2004-04-15 Impact factor: 12.531
Authors: Meri Varga; Peter Obrist; Stephan Schneeberger; Gilbert Mühlmann; Christina Felgel-Farnholz; Dominic Fong; Mathias Zitt; Thomas Brunhuber; Georg Schäfer; Guenther Gastl; Gilbert Spizzo Journal: Clin Cancer Res Date: 2004-05-01 Impact factor: 12.531
Authors: I Songun; S V Litvinov; C J H van de Velde; S T Pals; J Hermans; J H J M van Krieken Journal: Br J Cancer Date: 2005-05-09 Impact factor: 7.640
Authors: Daniel Brungs; Morteza Aghmesheh; Kara L Vine; Therese M Becker; Martin G Carolan; Marie Ranson Journal: J Gastroenterol Date: 2015-10-01 Impact factor: 7.527
Authors: Tetsunari Hase; Mitsuo Sato; Kenya Yoshida; Luc Girard; Yoshihiro Takeyama; Mihoko Horio; Momen Elshazley; Tomoyo Oguri; Yoshitaka Sekido; David S Shames; Adi F Gazdar; John D Minna; Masashi Kondo; Yoshinori Hasegawa Journal: Cancer Sci Date: 2011-06-02 Impact factor: 6.716
Authors: Ranju Ralhan; Helen C-H He; Anthony K-C So; Satyendra C Tripathi; Manish Kumar; Md Raghibul Hasan; Jatinder Kaur; Lawrence Kashat; Christina MacMillan; Shyam Singh Chauhan; Jeremy L Freeman; Paul G Walfish Journal: PLoS One Date: 2010-11-30 Impact factor: 3.240
Authors: Ranju Ralhan; Jun Cao; Terence Lim; Christina Macmillan; Jeremy L Freeman; Paul G Walfish Journal: BMC Cancer Date: 2010-06-25 Impact factor: 4.430